




Women with a History of Recurrent Pregnancy Loss Are a High-Risk Population for
Adverse Obstetrical Outcome
A Retrospective Cohort Study
Rasmark Roepke, Emma; Christiansen, Ole Bjarne; Källén, Karin; Hansson, Stefan R
Published in:
Journal of Clinical Medicine







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Rasmark Roepke, E., Christiansen, O. B., Källén, K., & Hansson, S. R. (2021). Women with a History of
Recurrent Pregnancy Loss Are a High-Risk Population for Adverse Obstetrical Outcome: A Retrospective Cohort
Study. Journal of Clinical Medicine , 10(2), [179]. https://doi.org/10.3390/jcm10020179
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to




Women with a History of Recurrent Pregnancy Loss Are a
High-Risk Population for Adverse Obstetrical Outcome:
A Retrospective Cohort Study
Emma Rasmark Roepke 1,2,*, Ole Bjarne Christiansen 3, Karin Källén 1 and Stefan R. Hansson 1,2


Citation: Rasmark Roepke, E.;
Christiansen, O.B.; Källén, K.;
Hansson, S.R. Women with a History
of Recurrent Pregnancy Loss Are a
High-Risk Population for Adverse
Obstetrical Outcome: A Retrospective
Cohort Study. J. Clin. Med. 2021, 10,
179. https://doi.org/10.3390/
jcm10020179
Received: 15 November 2020
Accepted: 27 December 2020
Published: 6 January 2021
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional clai-
ms in published maps and institutio-
nal affiliations.
Copyright: © 2021 by the authors. Li-
censee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Institute of Clinical Sciences Lund, Lund University, 22100 Lund, Sweden; karin.kallen@med.lu.se (K.K.);
stefan.hansson@med.lu.se (S.R.H.)
2 Department of Obstetrics and Gynaecology, Skåne University Hospital, Jan Waldenströmsgatan 47,
20502 Malmö, Sweden
3 Centre for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology,
Aalborg University Hospital, Clinical Institute at Aalborg University, 9220 Aalborg, Denmark; olbc@rn.dk
* Correspondence: emma.rasmark_ropke@med.lu.se; Tel.: +46-452-346-0721
Abstract: Recurrent pregnancy loss (RPL), defined as three or more consecutive miscarriages, is
hypothesized to share some of the same pathogenic factors as placenta-associated disorders. It has
been hypothesized that a defect implantation causes pregnancy loss, while a partially impaired
implantation may lead to late pregnancy complications. The aim of this retrospective register-based
cohort study was to study the association between RPL and such disorders including pre-eclampsia,
stillbirth, small for gestational age (SGA) birth, preterm birth and placental abruption. Women
registered with childbirth(s) in the Swedish Medical Birth Register (MFR) were included in the
cohort. Pregnancies of women diagnosed with RPL (exposed) in the National Patient Register
(NPR), were compared with pregnancies of women without RPL (unexposed/reference). Obstetrical
outcomes, in the first pregnancy subsequent to the diagnosis of RPL (n = 4971), were compared
with outcomes in reference-pregnancies (n = 57,410). Associations between RPL and placental
dysfunctional disorders were estimated by odds ratios (AORs) adjusting for confounders, with
logistic regression. RPL women had an increased risk for pre-eclampsia (AOR 1.45; 95% CI; 1.24–
1.69), stillbirth <37 gestational weeks (GWs) (AOR 1.92; 95% CI; 1.22–3.02), SGA birth (AOR 1.97;
95% CI; 1.42–2.74), preterm birth (AOR 1.46; 95% CI; 1.20–1.77), and placental abruption <37 GWs
(AOR 2.47; 95% CI; 1.62–3.76) compared with pregnancies by women without RPL. Women with RPL
had an increased risk of pregnancy complications associated with placental dysfunction. This risk
population is, therefore, in need of improved antenatal surveillance.
Keywords: recurrent pregnancy loss; pre-eclampsia; intrauterine growth restriction; preterm birth;
stillbirth; placental abruption
1. Introduction
Recurrent pregnancy loss (RPL) is defined as two [1,2] or, traditionally more strictly,
three or more consecutive miscarriages occurring before the fetus reaches viability [3]. The
later definition of three or more miscarriages is used in this study since this definition
is used in Sweden where the study is conducted. Other societies, such as the German,
Austrian and Swiss Society for Obstetrics and Gynecology as well as the British Royal
College for obstetrics and gynecology, support this definition [3,4].
RPL is distressing for the affected couples. About 0.5–2.3% [5–10] of women try-
ing to conceive suffer RPL. The most common risk factors underlying RPL are: parental
chromosomal aberrations, congenital and acquired uterine abnormalities, endocrine abnor-
malities, hereditary thrombophilia and autoimmune factors such as the antiphospholipid
syndrome [11]. However, in about half of the cases, investigations for RPL do not reveal
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any known etiology [12–14]. Insufficient placentation on an immunological basis has been
suggested as an additional explanation in this heterogeneous group [11,15].
Implantation and placentation are complex processes that depend on a two-way com-
munication between the embryo and the mother [16,17], regulated by reciprocal signaling
between decidua, immune cells, and the fetal trophoblast cells [18]. Vascular remodeling of
the spiral arteries by the extravillous trophoblast cells, plays a key role in successful implan-
tation and is crucial to secure a good pregnancy outcome [19,20]. It has been hypothesized
that a defect implantation causes pregnancy loss, while a partially impaired implantation
may lead to late pregnancy complications [20] such as pre-eclampsia, stillbirth, intrauterine
growth restriction (IUGR), preterm birth and placental abruption [19,21–23]. As miscarriage
and placental dysfunctional disorders seem to share some of the same pathophysiology, a
history of RPL might be associated with an increased risk of placenta-associated disorders.
Several studies supporting the abovementioned theory report a significantly higher
rate of pre-eclampsia [24–26], stillbirth [21,24,26,27], small for gestational age (SGA) in-
fants [14,21,24,26,28], preterm delivery [14,21,24,26–29] and placental abruption [24–26] in
women with three or more miscarriages.
Primary RPL is defined as no live birth before the recurrent miscarriages, and sec-
ondary RPL as at least one live birth before recurrent miscarriages. As a hypothesis, primary
and secondary RPL might differ in etiology and, therefore, risk of obstetrical complication
might differ [28]. This was recently emphasized in a large register study [30], finding
women with primary RPL to have a significantly increased risk of long-term diseases
following RPL, which was not seen in women with secondary RPL.
It is of great importance to know whether women with a history of RPL are at higher
risk for obstetrical complications and, therefore, in need of closer surveillance during
pregnancy.
In this large population-based register study, we aimed to investigate whether RPL
is associated with a higher than normal obstetrical risk. In addition, we also aimed to
compare pregnancy outcomes for primary and secondary RPL.
2. Material and Methods
This retrospective register-based cohort study used data from the Swedish Medical
Birth Register (MFR) and the Swedish National Patient Register (NPR) provided by the Na-
tional Board of Health and Welfare (NBHW). These registers can be linked at an individual
level through a unique personal identity number given to each Swedish resident [31].
The MFR contains data on more than 97% of all births in Sweden since 1973 [32],
including demographic data, information on reproductive history and complications
during pregnancy, delivery, and the neonatal period. A midwife records information
such as maternal weight, height, smoking habits, and medical and obstetric history from
antenatal visits, which is then reported to the MFR. After delivery, the responsible physician
or midwife records information about the women’s diseases and complications during
pregnancy and delivery, according to the International Classification of Diseases (ICD),
which is then forwarded to the MFR.
The NPR includes mandatory reported diagnosis codes, according to the ICD, from
each of the 21 county councils in Sweden. Since 1987, the NPR has included all inpatient
care in Sweden, and since 2001, the register has also covered outpatient visits, including
both private and public caregivers. The underreporting of inpatient data has been estimated
to be less than 1%. The rate of underreporting for outpatients has not been stated [33].
2.1. Study Population
The cohort included one group of women with childbirth and history of RPL (exposed)
and another reference group of women with childbirth but without the diagnoses of RPL
(unexposed). Women registered with ICD-10 codes of RPL, N96.9 or O26.2 in the NPR
during the period 2003–2012, and their childbirths registered in MFR, were included. A
reference group, without a history of RPL who had given birth, registered in the MFR
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during the above period, was randomly selected by the NBHW. Only singleton pregnancies
were included. In this study, we focused only on the first subsequent childbirth, following
the diagnosis of RPL. To be able to investigate RPL association to obstetric complications
in a subsequent pregnancy, childbirths before the miscarriages were excluded. All births
after the diagnoses of RPL could be of interest, although in this study, we focused only
on the first sequent childbirth. These pregnancies with variable outcomes were compared
with the pregnancies in the reference group. Women with primary and secondary RPL
were identified. As there are different risks of obstetrical complications for nulliparous
and multipara, women with primary RPL were compared with a nulliparous reference
group and women with secondary RPL were compared with a multipara reference group
to explore differences in obstetrical outcomes in primary vs. secondary RPL.
The quality of the diagnosis of RPL in the NPR has been evaluated with a positive
predictive value (PPV) of 85% (95% CI; 78–89%). A negative predictive value could not be
estimated due to the study design [34].
2.2. Outcome Variables
The main outcome measures were late pregnancy complications: pre-eclampsia, still-
birth, SGA birth, spontaneous preterm birth and placental abruption.
Pre-eclampsia was defined through ICD-10 codes, O14-O15, as a rise in blood pressure
(BP) (>140/90 mm Hg) combined with proteinuria (>0.3 g/24 h or +1 or more on dipstick)
on at least two occasions after the 20th week of gestation. A classification of severe pre-
eclampsia was given if one of the following occurred: systolic BP ≥ 160 mm Hg, diastolic
BP ≥ 110 mm Hg, oliguria (<500 mL/24 h), cerebral or visual symptoms, pulmonary edema,
severe epigastric pain, thrombocytopenia (<100 × 109/L), or increased liver enzymes (twice
upper normal level) [35].
The quality of the diagnosis of pre-eclampsia in the MFR has been validated with a
PPV of 93% [36].
Stillbirth was defined as fetal death after 22 completed gestational weeks (GWs) until
delivery; though before July 2008, the limit was after 28 GWs until delivery. The midwife or
physician assisting at the delivery registered stillbirth in a check box in the MFR, which was
used throughout the study. Fetal death during delivery was excluded from the analysis.
The term SGA was used and was considered to equate to IUGR and defined as birth
weight less than two standard deviations below the mean for the GWs according to growth
and development record charts [37]. Information on SGA or appropriate for gestational
age was missing in 313 (0.5%) births, which were assumed to be AGA. Both live born and
stillborn children were included in the analyses.
Preterm birth was defined as a birth before 37 completed GWs. The gestational age
was determined by routine ultrasound scans at around 18–21 GWs (97% of pregnant
women) but if this was not available, the last menstrual period was used for determining
the gestational age [38]. Very preterm birth was defined as a birth at 32 GWs or before, and
moderately preterm births from 32 to 36 GWs. Preterm birth was further subdivided into
those who had a spontaneous or iatrogenic start of delivery. At delivery, the responsible
midwife records the start of labor, which is labeled as spontaneous labor, induced or
Caesarean section, which makes it possible to identify women with spontaneous start. We
did not have information about preterm premature rupture of membranes. Those with
missing details on delivery start (4.7%) were assumed to have had a spontaneous start.
Those with missing details of gestational age at birth were assumed as term birth.
Placental abruption was defined through the ICD-10 code O45 as the separation of the
placenta from the maternal uterine attachment. Clinically, signs are uterine bleeding and
uterine muscle hypertonia with consequences as fetal distress or fetal death.
Information on the following maternal characteristics was extracted from the MFR:
maternal age, body mass index (BMI), nationality, smoking habits and assisted reproduc-
tion. Nationality was categorized into women born in Nordic countries (Sweden, Norway,
Finland, Denmark and Iceland) and non-Nordic countries (all others). Smokers were de-
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fined as women who were current smokers at the time of attendance at their first antenatal
visit. Assisted reproduction included in vitro fertilization (IVF) and intra-cytoplasmic
sperm injection (ICSI).
Data were extracted for medical disorders diagnosed with the ICD-10 codes or in check
boxes in the MFR. The medical disorders included chronic hypertension (ICD-10 code O10),
pre-gestational diabetes mellitus (type 1 ICD-10 code O24.0 and type 2 ICD-10 code O24.1),
asthma (ICD-10 code J45), cardiac disease (ICD-10 codes I50–51), renal disease (ICD-10
codes I12, N15), systemic lupus erythematosus (SLE) (ICD-10 code M32), antiphospholipid
syndrome (APLS) (ICD-10 code D68.6), thrombophilia (ICD-10 codes D68), inflammatory
bowel disease (IBD) (ICD-10 codes K50–51) and hypothyroidism (ICD-10 code E03).
2.3. Statistics
The association between RPL and the risk of pre-eclampsia, stillbirth, SGA birth,
spontaneous preterm birth and placental abruption were estimated in the first pregnancy
after the diagnosis of RPL. A comparison group without a history of RPL was used as a
reference.
Basic descriptive statistics were used to describe maternal characteristics, and a com-
parison between the study and the reference group plus primary and secondary RPL
group was made using the χ2-test. The risks of adverse obstetrical outcome according to
history of RPL were approximated by odds ratios (ORs) with 95% confidence intervals
(CIs). Since there were low initial risk of the obstetrical outcomes, ORs could be used
equivalent to relative risk. Subgroup analyses on women with primary RPL and secondary
RPL explored differences in the risk of obstetrical outcomes. Adjustment for confounding
factors was obtained by estimating the adjusted OR (AOR) in a stepwise unconditional
multiple logistic regression analysis. The following variables were included, when relevant,
in our regression model: maternal age, early pregnancy, BMI, smoking habits, the mother’s
nationality, assisted fertilization, chronic hypertension, and pre-gestational diabetes. These
factors were chosen because of their known or potential association with RPL and adverse
obstetrical outcomes. The regression model was adjusted to relevant confounder variables
for each different outcome. Factors with a univariable association with the outcome, p < 0.2,
were first selected for a multiple model. Then, a restricted model including only variables
with p < 0.2 was assessed.
Missing values were handled with imputed mean for BMI. This is eligible since the
frequency of missing data is low (about 10%), thus multiple imputations will not play
a significant difference. Women with no data on smoking habits were dealt with as a
separate variable in the model. Managing missing data for SGA and preterm birth have
been explained previously.
A value of p < 0.05 was considered significant. All analyses were performed using the
SPSS version 24 (Armonk, NY, USA: IMB Corp.)
2.4. Ethics
The study was approved by one of the regional ethical review boards in Lund, Sweden,
with reference number 2014/1. The ethical board waived the need for patient consent.
3. Results
This study included 62,381 pregnancies for analyses. There were a total of n = 4971
first subsequent pregnancies by women with RPL (exposed). The NBHW enabled to deliver
a random selection of about 5% of all childbirths in Sweden in the study period, which
resulted in the conducted unexposed group (n = 57,410 pregnancies) by women without
RPL. Pregnancies by women with RPL (n = 4971) were compared with pregnancies by
women without RPL (n = 57,410).
Of the 4971 women with a history of RPL and their first subsequent pregnancy in
MFR, 2334 (47%) and 2637 (53%) had primary and secondary RPL, respectively.
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3.1. Descriptive Statistics
Compared with women without a history of RPL, women with RPL were older, had
a higher BMI and lower parity. They were more likely to have gone through assisted
reproduction, to have chronic hypertension, hypothyroidism, asthma, APLS and pre-
gestational diabetes. Women with RPL were less likely to be smokers and less were born in
a Nordic country (Table 1.)
Table 1. Characteristics of women with RPL (recurrent pregnancy loss) and women without RPL at each pregnancy
identified in the Swedish Medical Birth Register and the Swedish National Patient Register.
Maternal Characteristics RPL a n = 4971 (%) No RPL a n = 57410 * (%) p-Value b Primary a n = 2335 (%) Secondary a n = 2636 (%) p-Value c
Age b,c
<25 303 (6.1) 11,621 (20.2) <0.001 226 (9.7) 77 (2.9) <0.001
25–29 907 (18.2) 15,541 (27.1) 532 (22.8) 375 (14.2)
30–34 1637 (32.9) 17,073 (29.7) 815 (34.9) 822 (31.2)
35–39 1499 (30.2) 10,493 (18.3) 541 (23.2) 958 (36.3)
>40 625 (12.6) 2682 (4.7) 221 (9.5) 404 (15.3)
Parity b
1 2335 (47.0) 24,510 (42.7) <0.001 2335 (100) 0 (0.0) -
2 1806 (36.3) 20,579 (35.8) - 1806 (68.5)
3 572 (11.5) 8025 (14.0) - 572 (21.7)
4+ 258 (5.2) 4296 (7.5) - 258 (9.8)
BMI b,c
<18.5 64 (1.3) 1407 (2.5) <0.001 37 (1.6) 27 (1.0) <0.001
18.5–24.9 2450 (49.3) 29,964 (52.2) 1192 (51.0) 1258 (47.7)
25.0–29.9 1314 (26.4) 12,187 (21.2) 557 (23.9) 757 (28.7)
>30.0 695 (14.0) 5494 (9.6) 312 (13.4) 383 (14.5)
Missing (or not recorded) 448 (9.0) 8358 (14.6) 237 (10.1) 211 (8.0)
Smoking b First antenatal
visit
Yes 300 (6.0) 5805 (10.1) <0.001 126 (5.4) 174 (6.6) 0.09
No 4417 (88.9) 48,412 (84.3) 2077 (89.0) 2340 (88.8)
Missing (or not recorded) 254 (5.1) 3193 (5.6) 132 (5.7) 122 (4.6)
Mother’s country of birth b
Nordic 3990 (80.3) 47067 (82) <0.05 1897 (81.2) 2093 (79.4) 0.10
Non-nordic 981 (19.7) 10,343 (18.0) 438 (18.8) 543 (20.6)
Assisted reproduction b
Yes 351 (7.1) 1327 (2.3) <0.001 269 (11.5) 82 (3.1) <0.001
No (or not recorded) 4620 (92.9) 56,083 (97.7) 2066 (88.5) 2554 (96.9)
Chronic hypertension
Yes 50 (1.0) 242 (0.4) <0.001 18 (0.8) 32 (1.2) 0.12
No (or not recorded) 4921 (99.0) 57,168 (99.6) 2317 (99.2) 2604 (98.8)
Pre-gestational diabetes b
Yes 43 (0.9) 314 (0.5) <0.05 18 (0.8) 25 (0.9) 0.50
No (or not recorded) 4928 (99.1) 57,096 (99.5) 2317 (99.2) 2611 (99.1)
Hypothyroidism b,c
Yes 211 (4.2) 528 (0.9) <0.001 128 (5.5) 83 (3.1) <0.001
No (or not recorded) 4760 (95.8) 56,882 (99.1) 2207 (94.5) 2553 (96.9)
SLE
Yes 9 (0.2) 55 (0.1) 0.072 3 (0.1) 6 (0.2) 0.41
No (or not recorded) 2962 (99.8) 57,355 (99.9) 2332 (99.9) 2630 (99.8)
IBD
Yes 41 (0.8) 353 (0.6) 0.073 18 (0.8) 23 (0.9) 0.69
No (or not recorded) 4930 (99.2) 57,057 (99.4) 2317 (99.2) 2613 (99.1)
Asthma b
Yes 435 (8.8) 3627 (6.3) <0.001 205 (8.8) 230 (8.7) 0.95
No (or not recorded) 4536 (91.2) 53,783 (93.7) 2130 (91.2) 2406 (91.3)
APLS b
Yes 11 (0.2) 3 (0.0) <0.001 5 (0.2) 6 (0.2) 0.92
No (or not recorded) 4960 (99.8) 57,407 (100) 2330 (99.8) 2630 (99.8)
Thrombophilia b,c
Yes 60 (1.2) 47 (0.1) <0.001 39 (1.7) 21 (0.8) <0.05
No (or not recorded) 4911 (98.8) 57,363 (99.9) 2296 (98.3) 2615 (99.2)
Heart disease
Yes 1 (0.0) 7 (0.0) 0.636 0 (0.0) 1 (0.0) 0.35
No (or not recorded) 2970 (100) 57,403 (100) 2335 (100) 2635 (100)
Kidney disease
Yes 34 (0.7) 288 (0.5) 0.085 18 (0.8) 16 (0.6) 0.48
No (or not recorded) 4937 (99.3) 57,122 (99.5) 2317 (99.2) 2620 (99.4)
RPL: recurrent pregnancy loss; BMI: body mass index; SLE: systemic lupus erythematosus; IBD: inflammatory bowel disease; APLS:
antiphospholipid syndrome. * Number of pregnancies by control women. Characteristics at each pregnancy in the control group. a First
childbirth after diagnosis with RPL in the National Patient Register; b p < 0.05 = significant difference between women diagnosed with RPL
and controls characteristics; c p < 0.05 = significant difference between primary and secondary RPL characteristics.
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Compared to women with secondary RPL, women with primary RPL were younger
and were less overweight. Women with primary RPL were more likely to have hypothy-




Compared with the reference group, women with a history of RPL had a higher risk
of pre-eclampsia (4.3% vs. 2.2%; AOR 1.45; 95% CI; 1.24–1.69). The same results were
seen after dividing pre-eclampsia into mild/moderate and severe. When occurrence of
pre-eclampsia was divided into those with preterm and term birth, the association between
a history of RPL and pre-eclampsia was much stronger in RPL patients with preterm birth,
showing a twofold increased risk compared to women without RPL (AOR 2.26; 95% CI;
1.70–3.01) (Table 2b).
Table 2. (a) Obstetrical outcome in the first subsequent pregnancy/childbirth after the diagnosis of recurrent pregnancy loss
(RPL) and pregnancies by women without RPL identified in the Swedish Medical Birth Register and the Swedish National
Patient Register; (b) Obstetrical outcome, in the first subsequent pregnancy after the diagnosis of recurrent pregnancy loss
(RPL) and pregnancies by women without RPL, with and without preterm birth.
Obstetrical Outcome RPL n = 4971 (%) No RPL n = 57,410 ** (%) Crude OR (95% CI) Adjusted OR (95% CI)
(a)
Pre-eclampsia a
No PE 4757 (95.7) 56,135 (97,8) 1.00 * 1.00 *
Any PE 1 214 (4.3) 1275 (2.2) 1.97 (1.70–2.28) 1.45 (1.24–1.69)
No PE 1.00 * 1.00 *
Mild/moderate PE 148 (3.0) 929 (1.6) 1.87 (1.57–2.23) 1.39 (1.17–1.68)
Severe PE 1 66 (1.3) 346 (0.6) 2.22 (1.70–2.90) 1.57 (1.20–2.07)
Stillbirth b
Live birth 4939 (99.4) 57,178 (99.6) 1.00 * 1.00 *
Stillbirth 32 (0.6) 232 (0.4) 1.60 (1.10–2.31) 1.38 (0.95–2.02)
SGA c
AGA or LGA 4800 (96.6) 56,001 (97.5) 1.00 * 1.00 *
SGA 171 (3.4) 1409 (2.5) 1.42 (1.21–1.66) 1.25 (1.06–1.47)
Preterm birth d
Term birth 2 4475 (90) 54,528 (95) 1.00 * 1.00 *
Preterm birth < 37 GWs 2 496 (10) 2882 (5.0) 2.10 (1.90–2.32) 1.95 (1.76–2.16)
Preterm birth 32–36 GWs 2 346 (7.0) 2482 (4.3) 1.70 (1.51–1.91) 1.62 (1.43–1.82)
Preterm birth < 32 GWs 2 150 (3.0) 398 (0.7) 4.59 (3.80–5.56) 3.86 (3.16–4.72)
Term birth 2 4475 (90) 54,528 (95) 1.00 * 1.00 *
Spontaneous preterm birth 281 (5.7) 1886 (3.3) 1.77 (1.56–2.02) 1.82 (1.59–2.08)
Iatrogenic preterm birth 215 (4.3) 996 (1.7) 2.23 (1.73–2.86) 2.16 (1.85–2.53)
Term birth 2 4475 54,528 1.00 * 1.00 *
Preterm birth 32–36 GWs 2 346 (7.0) 2482 (4.3) 1.70 (1.51–1.91) 1.62 (1.43–1.82)
Preterm birth <32 GWs 2 150 (3.0) 398 (0.7) 4.59 (3.80–5.56) 3.86 (3.16–4.72)
Placental abruption e
No placental abruption 4921 (99) 57,200 (99.6) 1.00 * 1.00 *
Placental abruption 50 (1.0) 210 (0.4) 2.77 (2.03–3.77) 2.45 (1.78–3.38)
(b)
Pre-eclampsia a
No PE *** 4759 (95.7) 56,140 (97.8) 1.00 * 1.00 *
PE and preterm 65 (1.3) 248 (0.4) 3.09 (2.35–4.07) 2.26 (1.70–3.01)
PE at term 147 (3.0) 1022 (1.8) 1.70 (1.42–2.02) 1.26 (1.05–1.51)
Stillbirth b
Live birth *** 4939 (99.4) 57,178 (99.6) 1.00 * 1.00 *
Stillbirth and preterm 24 (0.5) 126 (0.2) 2.21 (1.42–3.42) 1.92 (1.22–3.02)
Stillbirth at term 8 (0.2) 106 (0.2) 0.87 (0.43–1.79) 0.76 (0.37–1.57)
SGA c
No SGA *** 4800 (96.6) 56,001 (97.5) 1.00 * 1.00 *
SGA and preterm 75 (1.5) 343 (0.6) 2.55 (1.98–3.28) 2.00 (1.54–2.60)
SGA at term 96 (1.9) 1066 (1.9) 1.05 (0.85–1.30) 0.97 (0.78–1.20)
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Table 2. Cont.
Obstetrical Outcome RPL n = 4971 (%) No RPL n = 57,410 ** (%) Crude OR (95% CI) Adjusted OR (95% CI)
Placental abruption d
No PA *** 4921 (99) 57,200 (99.6) 1.00 * 1.00 *
PA and preterm 29 (0.6) 123 (0.2) 2.74 (1.83–4.11) 2.47 (1.62–3.76)
PA at term 21 (0.4) 87 (0.2) 2.81 (1.74–4.52) 2.42 (1.49–1.96)
1 Including eclampsia; 2 any delivery start (spontaneous, induction, Caesarean section). * reference; ** number of pregnancies by control
women, *** both birth at term and preterm. PE: pre-eclampsia; SGA: small for gestational age; AGA: appropriate for gestational age; LGA:
large for gestational age; GWs: gestational weeks. a Adjusted for age, parity, assisted conception, body mass index, mother’s country of
birth, chronic hypertension, pregestational diabetes, smoking; b adjusted for age, parity, body mass index, smoking; c adjusted for age,
parity, body mass index, smoking, mother’s country of birth, chronic hypertension; d adjusted for age, parity, body mass index, smoking; e
adjusted for age, parity, body mass index, smoking, chronic hypertension.
3.2.2. Stillbirth
The risk of preterm stillbirth, but not of stillbirth at term, was significantly higher
in women with RPL compared to references. The rates of a preterm stillbirth were 0.5%
vs. 0.2% in RPL women vs. reference women, respectively (AOR 1.92; 95% CI; 1.22–3.02)
(Table 2b).
3.2.3. Small for Gestational Age
Compared to the reference group, women with RPL had a higher risk of having a SGA
infant when it was born preterm but not when the gestational age was over 37 GWs: 1.5%
vs. 0.6% and 1.9% vs. 1.9%, respectively. The AOR for a preterm SGA infant was 2.00 (95%
CI; 1.54–2.60) (Table 2b).
3.2.4. Preterm Birth
Women with a history of RPL had a significantly higher risk for preterm birth than
women without RPL. The difference in risk was highest for very preterm birth (<32 GWs)
with AOR 3.86 (95% CI; 3.16–4.72) (Table 2a).
3.2.5. Placental Abruption
There was a higher rate of placental abruption in women with a history of RPL, 1.0%
vs. 0.4% AOR 2.45 (95% CI; 1.78–3.38). There was no change in the above risk in patients
with preterm vs. term birth (Table 2a).
3.2.6. Primary vs. Secondary RPL
The obstetrical outcomes for women with primary RPL were compared to nulliparous
in the reference group, and women with secondary RPL were compared with multiparous
in the reference group (Table 3). The risk of pre-eclampsia, preterm birth and placental
abruption were higher in both primary and secondary RPL compared with nulliparous
and multiparous references. The risk of SGA was significantly higher in the secondary RPL
group compared with the reference group (AOR 1.44 (95% CI; 1.11–1.88)) but not for the
primary RPL group (AOR 1.15 (95% CI; 0.92–1.43)).
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Table 3. Obstetrical outcome in women with primary and secondary recurrent pregnancy loss (RPL) in a subsequent pregnancy after the diagnoses of RPL, compared with nulliparous and
multiparous without RPL.
Obstetrical Outcome Primary RPLn = 2335 (%)
No RPL










n = 32,903 (%)
Crude OR (95% CI) Adjusted OR (95%CI)
Pre-eclampsia a
No PE 2192 (93.9) 23,710 (96.7) 1.00 * 1.00 * 2567 (97.4) 32,430 (98.6) 1.00 * 1.00 *
Any PE 1 143 (6.1) 797 (3.3) 1.94 (1.62–2.33) 1.45 (1.20–1.75) 69 (2.6) 473 (1.4) 1.84 (1.43–2.38) 1.42 (1.10–1.85)
No PE 1.00 * 1.00 * 1.00 * 1.00 *
mild/moderate 103 (4.4) 577 (2.4) 1.95 (1.58–2.41) 1.48 (1.19–1.85) 43 (1.6) 347 (1.0) 1.55 (1.12–2.13) 1.23 (0.89–1.70)
Severe 1 40 (1.7) 220 (0.9) 1.94 (1.38–2.72) 1.39 (0.98–1.98) 26 (1.0) 126 (0.4) 2.59 (1.69–3.96) 1.89 (1.22–2.92)
Stillbirth b
Live birth 2321 (99.4) 24,405 (99.6) 1.00* 1.00* 2618 (99.3) 32,773 (99.6) 1.00 * 1.00 *
Stillbirth 14 (0.6) 102 (0.4) 1.44 (0.82–2.53) 1.36 (0.76–1.41) 18 (0.7) 130 (0.4) 1.73 (1.06–2.84) 1.45 (0.87–2.40)
SGA c
No SGA 2233 (95.6) 23,649 (96.5) 1.00 * 1.00 * 2567 (97.4) 32,352 (98.3) 1.00 * 1.00 *
SGA 102 (4.4) 858 (3.5) 1.26 (1.02–1.55) 1.15 (0.92–1.43) 69 (2.6) 551 (1.7) 1.58 (1.23–2.03) 1.44 (1.11–1.88)
Preterm delivery d
Term birth 2066 (88.5) 23,005 (93.9) 1.00 * 1.00 * 2409 (91.4) 31,524 (95.8) 1.00 * 1.00 *
Preterm birth < 37 GW 269 (11.5) 1502 (6.1) 1.99 (1.74–2.29) 1.85 (1.60–2.13) 227 (11.5) 1380 (4.2) 2.15 (1.86–2.49) 2.07 (1.78–2.40)
Preterm birth 32–36 GW 170 (7.3) 1290 (5.2) 1.47 (1.24–1.73) 1.41 (1.19–1.68) 176 (6.7) 1192 (3.6) 1.93 (1.64–2.28) 1.86 (1.57–2.20)
Preterm birth < 32 GW 99 (4.2) 211 (0.9) 5.23 (4.10–6.66) 4.14 (3.20–5.37) 51 (1.9) 187 (0.6) 3.57 (2.61–4.88) 3.37 (2.44–4.66)
Placental abruption e
No placental abruption 2309 (98.9) 24,420 (99.6) 1.00 * 1.00 * 2612 (99.1) 32,780 (99.6) 1.00 * 1.00 *
Placental abruption 26 (1.1) 87 (0.4) 3.16 (2.04–4.91) 2.48 (1.57–3.92) 24 (0.9) 123 (0.4) 2.45 (1.68–3.80) 2.42 (1.54–3.79)
1 Including eclampsia. * reference. PE: pre-eclampsia; SGA: small for gestational age defined as infant <2 SD; AGA: appropriate for age; LGA: large for age. a Adjusted for age, smoking, body mass index, assisted
conception, mother’s country of birth, chronic hypertension, pre-gestational diabetes; b adjusted for age, smoking, body mass index; c adjusted for age, smoking, body mass index, mother’s country of birth,
assisted conception; d adjusted for age, smoking, body mass index, mother’s country of birth, assisted conception, e adjusted for age, smoking, body mass index.
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4. Discussion
4.1. Main Findings
Our study found RPL to be associated with an increased risk of placenta-associated
disorders. Compared to a reference group without RPL, the women with a history of RPL
had an increased risk of pre-eclampsia, preterm stillbirth (<37 GWs), SGA birth, preterm
birth and placental abruption in the first pregnancy subsequent to the diagnosis of RPL.
This association was stronger when the birth was preterm compared to term. Our results
support the hypothesis that RPL and placental-associated disorders have a partially shared
pathogenesis during implantation and placentation.
4.2. Strengths and Limitations
The major strength of this study is the large national register-based population with a
reference group from the same register. The large number of cases allowed analysis of less
common events, such as extreme preterm birth, stillbirth and placental abruption. It also
made it possible to subdivide the obstetrical outcomes into preterm and term disorders.
Some studies have used self-reported miscarriages to identify women with RPL [24,39]
which can entail a risk of bias. To minimize recall bias, this study used ICD-10 codes of
RPL, registered in the NPR by physicians, which were validated with a high PPV (85%) [34].
Another strength was the ability to adjust for important confounders such as maternal
age, smoking, BMI, conception by assisted reproduction and pre-gestational disorders; this
ability is often lacking in other studies [25,40]. However, information about other potential
confounders such as maternal socio-economic class and fetal sex were not available, and
other residual confounders may still persist.
The main weaknesses in this study are its retrospective design and the potential
missing register data. The RPL group is heterogeneous with several underlying causes
and it would therefore be of further interest to analyze whether subgroups with different
potential causes of RPL differ in terms of obstetrical outcomes, as well as to analyze if
there is a difference in obstetrical outcome for women with known and unknown RPL, as
some known causes, like APLS, can act as a confounder. APLS was possible to identify and
another analysis was made to adjust for this but no difference in the odds ratio was seen.
Other causes of RPL were, unfortunately, not possible to detect in this study due to lack of
information about different RPL risk factors.
4.3. Interpretation
Placental dysfunctional disorders can have severe consequences in pregnancy, af-
fecting both mother and infant. Therefore, it is of great importance to study associations
between potential risk groups, such as women with a history of RPL, and placental dysfunc-
tional disorders. A study by Gunnarsdottir et al. [24] investigated RPL and pre-eclampsia.
They found that the strongest association for pre-eclampsia was in patients with preterm
birth <37 GWs (AOR 1.62; 95% CI; 1.11–1.24) rather than in those with term births. Trogstad
et al. [39] found an increased risk for pre-eclampsia in RPL but only if there was a history
of assisted reproduction [39]. Two other studies [27,41] have failed to detect a higher risk
for pre-eclampsia in RPL women, which might be explained by the small population (42 of
women with RPL) [41] and the lack of a strict definition of consecutive miscarriages [27].
Our study showed an increased prevalence of pre-eclampsia in women with RPL (4.3%)
compared to controls (2.2%). The association with RPL was strongest for preterm and
severe pre-eclampsia (AOR 2.26; 95% CI; 1.70–3.01 and AOR 1.57; 95% CI; 1.20–2.07, re-
spectively), which was in accordance with results published by Sheiner et al. [25]. These
results support the use of increased antenatal surveillance in RPL and possible preventive
treatment for pre-eclampsia with low-dose aspirin [42].
Furthermore, our study identified a higher risk of stillbirth, preterm delivery and SGA
birth in RPL women compared with the reference group. This was equally in accordance
with several other studies [13,21,22,25,27,40,43]. Increased risk for stillbirth and SGA
infants was found in preterm birth (<37 GWs), although not at term (≥37 GWs) in our
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study, in line with the results of Gunnarsdottir et al. [24]. Additionally, we discovered the
strongest association between RPL and extreme preterm delivery (<32 GWs), also reported
by others [24,27]. These results support the view that antenatal care should screen women
with RPL for IUGR in the third trimester. It is well established that aspirin is beneficial in
reducing the risk of pre-eclampsia, IUGR, perinatal death and rates of spontaneous preterm
birth in women with historical risk factors [44–46]. Future studies need to evaluate whether
prophylactic treatment with aspirin can prevent or decrease the risk of these complications
in women with a history of RPL.
Placental abruption is a less common event during pregnancy. We found evidence for
a strong association, with an AOR > 2 for placental abruption comparing RPL with the
controls. As several other studies have supported our findings of an association between
placental abruption [24,25] and RPL, there is good evidence to manage women with RPL
as an obstetrical risk population.
When comparing primary RPL and secondary RPL with reference nulliparous and
multiparous, respectively, our results indicated that both primary and secondary RPL
was associated with an increased risk of premature birth, pre-eclampsia and placental
abruption. Association between primary RPL and preterm and SGA birth has been pre-
sented previously [28,40], although we could only find an significant association between
secondary RPL and SGA birth. Further studies need to investigate whether obstetrical
outcome differs between primary and secondary RPL, along with different etiologies of
RPL.
5. Conclusions
We found a clear association between RPL and adverse late pregnancy outcomes, prob-
ably related to a defective placentation. There is evidence for managing women with RPL
as a risk population for placenta-associated complications. This is presently not routinely
done in Swedish antenatal care. However, detailed suggestions for a surveillance program
are beyond the scope of this study. However, RPL women seem to be in need of increased
antenatal surveillance to reduce the risk of pregnancy complications. Hopefully, enhanced
antenatal care with better screening of the obstetrical history can help to decrease placental
dysfunctional disorders. After clinical implementation of a surveillance program address-
ing risk factors, future studies are needed to evaluate the effect of increased antenatal care
in women with RPL, including prophylactic treatment.
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